Reviewing DiaMedica Therapeutics (NASDAQ:DMAC) & Aravive (NASDAQ:ARAV)

DiaMedica Therapeutics (NASDAQ:DMAC) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, valuation and risk.

Analyst Ratings

This is a summary of recent ratings and price targets for DiaMedica Therapeutics and Aravive, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
DiaMedica Therapeutics	1	0	5	0	2.67
Aravive	0	0	0	0	0.00

DiaMedica Therapeutics currently has a consensus target price of $12.33, suggesting a potential upside of 92.11%. Given DiaMedica Therapeutics’ stronger consensus rating and higher possible upside, equities research analysts plainly believe DiaMedica Therapeutics is more favorable than Aravive.

Profitability

This table compares DiaMedica Therapeutics and Aravive’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
DiaMedica Therapeutics	N/A	-77.72%	-69.54%
Aravive	N/A	N/A	N/A

Earnings & Valuation

This table compares DiaMedica Therapeutics and Aravive”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
DiaMedica Therapeutics	N/A	N/A	-$32.77 million	($0.70)	-9.17
Aravive	N/A	N/A	N/A	($0.90)	-0.04

DiaMedica Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

10.1% of DiaMedica Therapeutics shares are owned by institutional investors. Comparatively, 35.8% of Aravive shares are owned by institutional investors. 5.0% of DiaMedica Therapeutics shares are owned by insiders. Comparatively, 60.4% of Aravive shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

Aravive beats DiaMedica Therapeutics on 5 of the 9 factors compared between the two stocks.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

About Aravive

Aravive, Inc., a clinical-stage biopharmaceutical company, develops transformative treatments for life-threatening diseases, including cancer and fibrosis in the United States. Its lead product candidate is batiraxcept, an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway, which is in Phase III clinical trial for the treatment of platinum- resistant recurrent ovarian cancer; and in Phase Ib/II clinical trial for the treatment of clear cell renal cell carcinoma and pancreatic adenocarcinoma. The company also develops AVB-S6, a soluble Fc-fusion protein to block the activation of the GAS6-AXL signaling pathway. It has a license and collaboration agreement with WuXi Biologics (Hong Kong) Limited to identify and develop novel high-affinity bispecific antibodies targeting cancer and fibrosis; and license agreement with 3D Medicines Inc. to develop products that contain batiraxcept as the sole drug substance for the treatment of human oncological diseases in mainland China, Taiwan, Hong Kong, and Macau. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. was incorporated in 2008 and is headquartered in Houston, Texas.